Dergiler / European Archives of Medical Research / 2019 / Cilt: 35 - Sayı: 3

Non-urothelial Bladder Cancers: Single Center Experience

Sayfa
162–166
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In the light of these results, we recommend that these patientsshould participate in prospective clinical studies.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Bladder cancers are classified into two groups as urothelial and non-urothelial cancer (NUBC).
📊
Temel Bulgular & Veri:In this study, we investigated the clinicopathological featuresand treatment responses in patients with NUBC who were diagnosed and treated in our center.Methods: The patients who were diagnosed and treated in our hospital between 2006 and 2017 were included in the study retrospectively.
💡
Sonuç & Katkı:In the light of these results, we recommend that these patientsshould participate in prospective clinical studies.
🔬Tür:Araştırma Makalesi
📍Kapsam:2006 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Bladder cancers are classified into two groups as urothelial and non-urothelial cancer (NUBC). In this study, we investigated the clinicopathological featuresand treatment responses in patients with NUBC who were diagnosed and treated in our center.Methods: The patients who were diagnosed and treated in our hospital between 2006 and 2017 were included in the study retrospectively. Patients with urothelial ormixed bladder cancers were excluded from the study.Results: A total of 16 patients with NUBC were included in the study. Six patients had squamous cell carcinoma, six patients had small cell carcinoma and four patientshad adenocarcinoma. Thirteen patients (81%) were male and three were female. Although there was no statistically significant difference between the groups in terms oflocalization of metastases (p=0.663), the most common site of metastasis was pelvic structures in squamous cell carcinoma group and multiple distant organ metastasiswere observed in small cell carcinoma group. The median survival in squamous cell carcinoma, adenocarcinoma, and small cell carcinoma was 11±5.3, 12±10, and2±1.8 months, respectively (logrank p=0.329).Conclusion: There are no large prospective randomized clinical studies to guide treatment in NUBC. In the light of these results, we recommend that these patientsshould participate in prospective clinical studies.

🔖

Bu Makaleye Atıf Yap

CAN, O., DEMİREL, C., ARICI, S., SEÇMELER, Ş., YAŞAR, N., GEREDELİ, Ç., SAKİN, A. (2022). Non-urothelial Bladder Cancers: Single Center Experience. European Archives of Medical Research, Cilt: 35 - Sayı: 3, 162–166. https://ajindex.com/articles/510448

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol 2003;44:672-81
  2. Ghoneim MA, Ashamallah AK, Awaad HK, Whitmore WF Jr. Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J Urol 1985;134:266-8
  3. Loh KP, Mondo E, Hansen EA, Sievert L, Fung C, Sahasrabudhe DM, et al. Targeted Therapy Based on Tumor Genomic Analyses in Metastatic Urachal Carcinoma. Clin Genitourin Cancer 2016;14:e449-52
  4. Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer 2004;101:957-62
  5. Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 2005;103:1172-8
  6. Ozbey I, Aksoy Y, Polat O, Biçgi O, Demirel A. Squamous metaplasia of the bladder: findings in 14 patients and review of the literature. Int Urol Nephrol 1999;31:457-61
  7. Kantor AF, Hartge P, Hoover RN, Fraumeni JF Jr. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res 1988;48:3853-5
  8. Scosyrev E, Yao J, Messing E.Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology 2009;73:822-7
  9. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:1477-88
  10. Serretta V, Pomara G, Piazza F, Gange E. Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases. Eur Urol 2000;37:85-9
  11. Grignon DJ, Ro JY, Ayala AG, Johnson DE, Ordóñez NG. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991;67:2165-72
  12. Xiaoxu L, Jianhong L, Jinfeng W, Klotz LH. Bladder adenocarcinoma: 31 reported cases. Can J Urol 2001;8:1380-3
  13. Zaghloul MS, Nouh A, Nazmy M, Ramzy S, Zaghloul AS, Sedira MA, et al. Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol 2006;24:13-20
  14. Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology 2007;69:255-9
  15. Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park SH, et al. Palliative chemotherapy for